Survival and risk of vascular complications in myelofibrosis—A <scp>population‐based</scp> study from the Swedish <scp>MPN</scp> group

Marie Lindgren(Umeå University), Erik Ahlstrand(Örebro University), Carolina Bentham(Varberg Hospital), Jan Samuelsson(Karolinska University Hospital), Anneli Enblom‐Larsson(Umeå University), Anna Ravn Landtblom(Karolinska University Hospital), Helna Pettersson(NU Hospital Group), Björn Andréasson(NU Hospital Group), Stefan Scheding

European Journal Of Haematology

June 13, 2022

10.1111/ejh.13813

Cited by 5

Related Papers

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

|Journal of Clinical Oncology|2012|461

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

|Blood|2011|340

Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients

|Blood|1998|306

Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms

|Journal of Clinical Oncology|2011|244

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

|The Lancet|2023|194